Early Detection Research Network

Proteomics Biomarker Development Laboratory

Proteomics Biomarker Development Laboratory
53

No lead investigator defined.

No coordinating investigator defined.

No involved investigator sites defined.

No design specified.
UNKNOWN

The Biomarker Development Laboratory is focused on the <br>application of a proteomic approach for the development<br> of cancer biomarkers. The laboratory will apply <br>technologies for protein analysis to the detection and <br>identification of proteins secreted by tumor cells and <br>protein antigens that induce a humoral response in tumor<br>s. The initial targeted tumor types for the identification<br> of potential biomarker proteins are: Colon, esophagus,<br> ovary, lung, breast and liver. The proposed studies will<br> make heavy utilization of two-dimensional (2-D) protein<br> analysis, of protein identification technologies and of <br>database capabilities that have been developed by the <br>applicant group. The objectives of this research are <br>to 1. Identify tumor antigens that induce a humoral <br>response; 2. Identify tumor secreted proteins and develop<br>a database; 3. Preliminarily validate the potential utility<br>of markers for early cancer detection. Sixty ml of blood<br>will be obtained from healthy normals, and from small <br>cell lung cancer, hepatoma, esophageal, and breast cancer<br>patients, and from ovarian, colon, and non-small cell lung<br>cancer patients prior to surgical resection and six to<br>ten weeks after resection. Demographic data, sera and <br>DNA will be used in 2-D protein analysis to identify new<br>or altered proteins. The initial validation will be the <br>assay of the presence or absence of a given protein in a<br>large sample cohort from the samples collected from these<br>patients. There is no specified age range, although the <br>diseases under study do not occur in children. No subjects<br>will be excluded on the basis of race or gender. Women<br>of child bearing age will be studied. Linkable demographic<br>data will be held separately from the bar-coded serum or<br>DNA samples. Serum and DNA sample will be identifiable<br>only by subject identification number. Full written <br>informed consent will be obtained from patients.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.